{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,3]],"date-time":"2026-05-03T14:00:34Z","timestamp":1777816834382,"version":"3.51.4"},"reference-count":19,"publisher":"BMJ","issue":"2","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Br J Ophthalmol"],"published-print":{"date-parts":[[2018,2]]},"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Intravitreal bevacizumab (IVB) has emerged as an effective treatment modality for the management of retinopathy of prematurity (ROP) where the disease is severe and posterior. Despite evidence of systemic vascular endothelial growth factor suppression and concerns about how this might affect the developing neonate, the optimal dose is unknown to date. We report our experience of using ultra-low-dose (0.16\u2009mg) IVB, one-quarter of the \u2018standard\u2019 dose that has widely been reported in the treatment of ROP.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A retrospective observational case series of consecutive infants who underwent ultra-low-dose IVB injection for the management of ROP at a regional neonatal intensive care unit in the North East of England, between November 2013 and August 2016.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>29 eyes of 15 infants underwent IVB injection. We defined \u2018treatment success\u2019 as complete regression of retinopathy and vascularisation into (or laser ablation of) zone 3. Primary success (in response to IVB 0.16\u2009mg alone) was observed in 23\/29 eyes (79.3%). Secondary success (where additional treatment was required) was observed in 27\/29 eyes (93.1%). One infant died of respiratory disease during follow-up. Retreatment occurred in 6\/29 eyes (20.6%). Retreatments occurred at a mean of 9.8 weeks after initial IVB (range 6\u201315) and at a mean of 44 weeks postmenstrual age (range 40\u201350).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>0.16\u2009mg IVB is effective in the treatment of severe and posterior ROP, with no adverse ocular outcomes occurring in our series.<\/jats:p><\/jats:sec>","DOI":"10.1136\/bjophthalmol-2017-310408","type":"journal-article","created":{"date-parts":[[2017,6,28]],"date-time":"2017-06-28T00:40:17Z","timestamp":1498610417000},"page":"260-264","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":21,"title":["Ultra-low-dose intravitreal bevacizumab for the treatment of retinopathy of prematurity: a case series"],"prefix":"10.1136","volume":"102","author":[{"given":"Roxane J","family":"Hillier","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alan J","family":"Connor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ayad E","family":"Shafiq","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2017,6,27]]},"reference":[{"key":"2020050713003256000_102.2.260.1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1007374"},{"key":"2020050713003256000_102.2.260.2","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/j.jaapos.2016.10.002","article-title":"Retinopathy of prematurity: intravitreal injections of bevacizumab: timing, technique, and outcomes","volume":"20","author":"Mintz-Hittner","year":"2016","journal-title":"J Aapos"},{"key":"2020050713003256000_102.2.260.3","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1167\/iovs.15-18528","article-title":"Assessment of plasma cytokine Profile changes in Bevacizumab-Treated Retinopathy of Prematurity Infants","volume":"57","author":"Kong","year":"2016","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"2020050713003256000_102.2.260.4","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1097\/IAE.0000000000001209","article-title":"Serum vascular endothelial growth factor after bevacizumab or ranibizumab treatment for retinopathy of prematurity","volume":"37","author":"Wu","year":"2017","journal-title":"Retina"},{"key":"2020050713003256000_102.2.260.5","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2011.07.005"},{"key":"2020050713003256000_102.2.260.6","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2015-3218"},{"key":"2020050713003256000_102.2.260.7","doi-asserted-by":"crossref","unstructured":"Lien R , Yu MH , Hsu KH , et al . Neurodevelopmental outcomes in infants with retinopathy of Prematurity and Bevacizumab treatment. PLoS One 2016;11:e0148019.doi:10.1371\/journal.pone.0148019","DOI":"10.1371\/journal.pone.0148019"},{"key":"2020050713003256000_102.2.260.8","doi-asserted-by":"publisher","DOI":"10.1159\/000101344"},{"key":"2020050713003256000_102.2.260.9","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1016\/j.ophtha.2016.04.028","article-title":"Clinical management of recurrent retinopathy of prematurity after Intravitreal Bevacizumab Monotherapy","volume":"123","author":"Mintz-Hittner","year":"2016","journal-title":"Ophthalmology"},{"key":"2020050713003256000_102.2.260.10","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2014.05.015"},{"key":"2020050713003256000_102.2.260.11","doi-asserted-by":"crossref","first-page":"2042","DOI":"10.1016\/j.ophtha.2016.04.024","article-title":"Does Bevacizumab Alter Vascularization potential in Retinopathy of Prematurity?","volume":"123","author":"Isaac","year":"2016","journal-title":"Ophthalmology"},{"key":"2020050713003256000_102.2.260.12","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1038\/eye.2016.173","article-title":"Globe size and bevacizumab treatment in retinopathy of prematurity: should we adjust the dose?","volume":"30","author":"Connor","year":"2016","journal-title":"Eye"},{"key":"2020050713003256000_102.2.260.13","first-page":"233","article-title":"Final results of the early treatment for Retinopathy of Prematurity (ETROP) randomized trial","volume":"102","author":"Good","year":"2004","journal-title":"Trans Am Ophthalmol Soc"},{"key":"2020050713003256000_102.2.260.14","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1111\/aos.12266","article-title":"Intravitreal low-dosage bevacizumab for retinopathy of prematurity","volume":"92","author":"Harder","year":"2014","journal-title":"Acta Ophthalmol"},{"key":"2020050713003256000_102.2.260.15","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1097\/IAE.0000000000001126","article-title":"Retinal vascular development with 0.312 mg intravitreal bevacizumab to treat severe posterior retinopathy of prematurity: a longitudinal fluorescein angiographic study","volume":"37","author":"Lorenz","year":"2017","journal-title":"Retina"},{"key":"2020050713003256000_102.2.260.16","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.jaapos.2016.09.012","article-title":"A lower dose of intravitreal bevacizumab effectively treats retinopathy of prematurity","volume":"20","author":"Khodabande","year":"2016","journal-title":"J Aapos"},{"key":"2020050713003256000_102.2.260.17","doi-asserted-by":"crossref","unstructured":"Han J , Kim SE , Lee SC , et al . Low dose versus conventional dose of intravitreal bevacizumab injection for retinopathy of prematurity: a case series with paired-eye comparison. Acta Ophthalmol 2016 (Epub ahead of print: 24 Mar 2016).doi:10.1111\/aos.13004","DOI":"10.1111\/aos.13004"},{"key":"2020050713003256000_102.2.260.18","doi-asserted-by":"crossref","first-page":"e20","DOI":"10.3928\/01913913-20150421-11","article-title":"Ultra-low dose of intravitreal bevacizumab in the treatment of retinopathy of prematurity","volume":"52","author":"Connor","year":"2015","journal-title":"J Pediatr Ophthalmol Strabismus"},{"key":"2020050713003256000_102.2.260.19","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1208129"}],"container-title":["British Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bjophthalmol-2017-310408","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,30]],"date-time":"2022-07-30T02:40:49Z","timestamp":1659148849000},"score":1,"resource":{"primary":{"URL":"https:\/\/bjo.bmj.com\/lookup\/doi\/10.1136\/bjophthalmol-2017-310408"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6,27]]},"references-count":19,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2018,1,24]]},"published-print":{"date-parts":[[2018,2]]}},"alternative-id":["10.1136\/bjophthalmol-2017-310408"],"URL":"https:\/\/doi.org\/10.1136\/bjophthalmol-2017-310408","relation":{},"ISSN":["0007-1161","1468-2079"],"issn-type":[{"value":"0007-1161","type":"print"},{"value":"1468-2079","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,6,27]]}}}